Medical Condition News

RSS

Nymox Pharmaceutical's NX-1207 human clinical trials for HCC demonstrate favorable safety data

Nymox Pharmaceutical Corporation outlined today the Company's development program for the Company's lead drug candidate, NX-1207, currently in Phase 3 trials in the U.S. for the treatment of benign prostatic hyperplasia (BPH). The drug has been successful in a series of blinded controlled multi-center U.S. clinical trials where it has been found to produce improvements that are about double that reported for currently approved BPH drugs.

31 Mar 2010

BVA unveils wide-view neurostimulator concept, prototype bionic eye

Bionic Vision Australia today unveils their wide-view neurostimulator concept - a bionic eye that will be implanted into Australia's first recipient of the technology.

31 Mar 2010

Drinking orange juice with fast-food meal may help prevent vascular inflammation

Eating foods containing flavonoids -- orange juice, in this case -- along with a high-fat, high-carbohydrate fast-food meal neutralizes the oxidative and inflammatory stress generated by the unhealthy food and helps prevent blood vessel damage, a new study by University at Buffalo endocrinologists shows.

31 Mar 2010

PMDD often misdiagnosed as major depression or other mood disorder

As science slowly, but continually, unravels the causes of disorders, it increasingly teases apart biological threads that, when spooled together, begin to take on the warp and weft of separate disorders.

31 Mar 2010

AgaMatrix, sanofi-aventis announce long-term partnership for BGM solutions

AgaMatrix, Inc. and sanofi-aventis today announced that they have signed a long-term agreement for the development, supply and commercialization of blood glucose monitoring (BGM) solutions. Under the terms of the agreement, AgaMatrix and sanofi-aventis will co-develop innovative solutions in diabetes management that incorporate AgaMatrix's WaveSense™ technology. Sanofi-aventis will commercialize through its Global Diabetes Division such integrated solutions for patients with diabetes, along with current sanofi-aventis insulins and delivery devices.

31 Mar 2010

Gore launches new consumer website to serve as patient resource on AAA

W. L. Gore & Associates announced the launch of a new consumer website, http://www.ultimatesaaave.com, which will serve as an enhanced patient resource on Abdominal Aortic Aneurysm.

31 Mar 2010

NKF 2010 Spring Clinical Meeting: Multiple posters on Hematide/peginesatide to be presented

Affymax, Inc. and Takeda Pharmaceuticals Global Research & Development Center, Inc., U.S., today announced multiple posters on Hematide™/peginesatide have been accepted for presentation at the National Kidney Foundation (NKF) 2010 Spring Clinical Meeting taking place April 13-17, 2010 in Orlando, Florida. Hematide is an investigational agent for the treatment of anemia in chronic renal failure (also referred to as renal anemia).

31 Mar 2010

Hsp90 inhibitors may help fight cardiovascular disease, say researchers

New drugs that are helping fight a multi-front war on cancer may do the same for cardiovascular disease, Medical College of Georgia researchers said.

31 Mar 2010

Depomed licensee submits DM-1796 NDA for management of PHN

Depomed, Inc. today announced that its licensee has submitted a New Drug Application (NDA) for DM-1796 to the U.S. Food and Drug Administration (FDA) for the management of postherpetic neuralgia (PHN), or pain after shingles. DM-1796 is an investigational, extended release, once-daily tablet formulation of gabapentin designed to reduce dosing frequency and have a low incidence of side effects.

31 Mar 2010

Nutra Pharma's Cobroxin pain reliever now available at CVS stores

Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy, HIV and Multiple Sclerosis, has announced today that its over-the-counter pain reliever, Cobroxin, is now available for purchase in CVS.

31 Mar 2010

Patients switching to Victoza experience further reductions in A1c and weight loss

Diabetes Care published online the results of the Novo Nordisk LEAD™ 6 extension study, which evaluated the efficacy and safety of switching from exenatide, which is taken twice a day, to once-daily Victoza®. Results show that when added to oral antidiabetes drugs, patients who switched from exenatide to Victoza experienced further reductions in A1c and weight loss.

31 Mar 2010

Overweight infants may experience delayed motor skills

Those cute little rolls of fat some infants have may actually slow their ability to crawl and walk, according to a new study by the University of North Carolina at Chapel Hill.

31 Mar 2010

Study indicates estrogenic drug could help treat schizophrenia

An estrogenic drug that influences neurotransmitter and neuronal systems in the brain is showing promise as an effective therapy for women who suffer from schizophrenia.

31 Mar 2010

QRxPharma initiates Phase 1 trial for evaluating PK profiles of morphine, oxycodone CR formulations

QRxPharma announced today initiation of the Company's first Phase 1 trial to evaluate the pharmacokinetic (PK) profiles of experimental controlled-release (CR) morphine and oxycodone formulations that will be incorporated into MoxDuo®CR. MoxDuo®CR contains a fixed 3:2 morphine:oxycodone combination and is intended to be dosed twice daily in patients experiencing chronic pain, an approximately US$7 billion dollar market worldwide.

31 Mar 2010

Vision CRC scientists discover new technology to control myopia

Scientists from the Vision Cooperative Research Centre in Australia today announced that myopia, or short-sightedness, can be controlled with new technology. This ground breaking discovery was based on research conducted by Vision CRC partners - the University of Houston College of Optometry and the Brien Holden Vision Institute, located at the University of New South Wales.

31 Mar 2010

Women, diabetics, dementia patients most likely to fall in 'doughnut hole'; Reform seeks to close coverage gap

Among elderly Americans, women and those with diabetes and dementia are most likely to find themselves in the Medicare Part D drug plan 'doughnut hole,' the coverage gap that occurs after a beneficiary has reached the annual coverage limit but hasn't spent enough on drugs to qualify for catastrophic coverage.

31 Mar 2010

Titan Pharmaceuticals commences Phase 3 study of Probuphine for opioid addiction

Titan Pharmaceuticals, Inc. today announced the initiation of a randomized, placebo and active controlled, multi-center Phase 3 clinical study of Probuphine in the treatment of opioid addiction. This confirmatory Phase 3 study will be conducted at approximately 23 sites in the United States and randomize approximately 250 patients into three arms: Probuphine (100 patients), Suboxone® (100 patients) and placebo (50 patients).

31 Mar 2010

SpineAlign Medical announces VerteLift as new name for vertebral implant system

SpineAlign Medical Inc. announced today that it has chosen a new trademark name, VerteLift, for its vertebral implant system. Formerly called the SpineAlign System, the name reflects the advantages of the product that the Company will leverage going forward.

30 Mar 2010

Novo Nordisk BlueSheet launched to provide information on diabetes and chronic disease

Novo Nordisk, a global healthcare company and leader in diabetes care, today announced the launch of the Novo Nordisk BlueSheet, a resource for information on diabetes and chronic disease, highlighting key issues in diabetes prevention, detection, treatment and care.

30 Mar 2010

CTRC initiates patient enrolment in U.S. Phase 2 clinical trial of REOLYSIN

Oncolytics Biotech Inc. announced today that the Cancer Therapy & Research Center at the University of Texas Health Science Center has started patient enrolment in a U.S. Phase 2 clinical trial using intravenous administration of REOLYSIN(R) in combination with carboplatin and paclitaxel in patients with squamous cell carcinoma of the lungs.

30 Mar 2010

Medical Condition News

Nymox Pharmaceutical's NX-1207 human clinical trials for HCC demonstrate favorable safety data

BVA unveils wide-view neurostimulator concept, prototype bionic eye

Drinking orange juice with fast-food meal may help prevent vascular inflammation

PMDD often misdiagnosed as major depression or other mood disorder

AgaMatrix, sanofi-aventis announce long-term partnership for BGM solutions

Gore launches new consumer website to serve as patient resource on AAA

NKF 2010 Spring Clinical Meeting: Multiple posters on Hematide/peginesatide to be presented

Hsp90 inhibitors may help fight cardiovascular disease, say researchers

Depomed licensee submits DM-1796 NDA for management of PHN

Nutra Pharma's Cobroxin pain reliever now available at CVS stores

Patients switching to Victoza experience further reductions in A1c and weight loss

Overweight infants may experience delayed motor skills

Study indicates estrogenic drug could help treat schizophrenia

QRxPharma initiates Phase 1 trial for evaluating PK profiles of morphine, oxycodone CR formulations

Vision CRC scientists discover new technology to control myopia

Women, diabetics, dementia patients most likely to fall in 'doughnut hole'; Reform seeks to close coverage gap

Titan Pharmaceuticals commences Phase 3 study of Probuphine for opioid addiction

SpineAlign Medical announces VerteLift as new name for vertebral implant system

Novo Nordisk BlueSheet launched to provide information on diabetes and chronic disease

CTRC initiates patient enrolment in U.S. Phase 2 clinical trial of REOLYSIN

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News